Nyxoah Wins Default Judgment Against Inspire in European Patent Case
NYXH is trading near its 52-week low of $0.8 (12% above the low) on light trading volume (0.1× avg).
Summary
The Unified Patent Court in Munich issued a default judgment in Nyxoah's favor in its patent infringement case against Inspire Medical Systems over European Patent 2 760 534. Nyxoah said it is still evaluating how to enforce the ruling, so the practical benefit is unclear — a default judgment typically reflects the other side's failure to respond rather than a full merits win. The stock rose 3.2% in extended trading while Inspire fell about 2%, a modest reaction for a company with a sub-$100M market cap. This lands after a rough stretch: Nyxoah cut 2026 revenue guidance to €33-35M from €36-40M on October 20 and has just installed Liam Kelly as CEO effective October 1.
At the time of this announcement, NYXH was trading at $0.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.6M. The 52-week trading range was $0.80 to $5.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.